289 (PB069) - The ABCB1/ABCG2 inhibitor elacridar is a more potent pharmacoenhancer compared to tariquidar for treatment of intracranial tumors with small molecule drugs
| Autor: | Van Tellingen, O., Lentzas, A., Zuidema, S., Çitirikkaya, C., Venekamp, N., Beijnen, J. |
|---|---|
| Zdroj: | In European Journal of Cancer October 2022 174 Supplement 1:S103-S103 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect